Jie Li

Jie Li

Auto-generated profile, based on publicly available information

Jie Li

Department of Hematology , Nanfang Hospital, Southern Medical University , Guangzhou 510515 , China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2017 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
YLYin Li
Yin Li
YWYan Wang
Yan Wang
YZYong Zhou
Yong Zhou
JLJie Li
Jie Li
KCKai Chen
Kai Chen
BXBing Xu
Bing Xu
Many conventional chemotherapeutic drugs are known to be involved in DNA damage, thus ultimately leading to apoptosis of leukemic cells. However, they fail to completely eliminate leukemia stem cells (LSCs) due to their higher DNA repair capacity of cancer stem cells than that of bulk cancer cells, which becomes the root of drug resistance and leukemia recurrence. A new strategy to eliminate LSCs in acute myeloid leukemia (AML) is therefore urgently needed. We report that a low-dose chidamide, a novel orally active benzamide-type histone deacetylase (HDAC) inhibitor, which selectively targets HDACs 1, 2, 3, and 10, could enhance the cytotoxicity of DNA-damaging agents (daunorubicin, idarubicin, and cytarabine) in CD34+CD38− KG1α cells, CD34+CD38− Kasumi cells, and primary refractory or relapsed AML CD34+ cells, reflected by the inhibition of cell proliferation, induction of apoptosis, and increase of cell cycle arrest in vitro. Mechanistically, these events were associated with DNA damage accumulation and repair defects. Co-treatment with chidamide and the DNA-damaging agent IDA gave rise to the production of γH2A.X and inhibited posttranslationally but not transcriptionally the repair gene of ATM, BRCA1, and checkpoint kinase 1 (CHK1) and 2 (CHK2) phosphorylation. Finally, the combination of chidamide and IDA initiated caspase-3 and PARP cleavage, but not caspase-8 and caspase-9, and ultimately induced CD34+CD38− KG1α cell apoptosis. Further analysis of AML patients’ clinical characteristics revealed that the ex vivo efficacy of chidamide in combination with IDA in primary CD34+ samples was significantly correlated to peripheral blood WBC counts at diagnosis, while LDH levels and karyotype status had no effect, indicating that the combination regimen of chidamide and IDA could rapidly diminish tumor burden in patients with R/R AML. These findings provide preclinical evidence for low-dose chidamide in combination with chemotherapeutic agents in treating recurrent/resistant AML as an alternative salvage regimen, especially those possessing stem and progenitor cells.

14 April 2022 in Biomedical Engineering / Biomedizinische Technik
Verified
Journal Article
Closed access
LGLiang Guo
Liang Guo
PHPeiduo Huang
Peiduo Huang
HHHaisen He
Haisen He
QLQinghang Lu
Qinghang Lu
ZSZhihao Su
Zhihao Su
JLJie Li
Jie Li
Bone marrow cell morphology has always been an important tool for the diagnosis of blood diseases. Still, it requires years of experience from a suitable person. Furthermore, the outcomes of their recognition are subjective and there is no objective quantitative standard. As a result, developing a deep learning automatic classification system for bone marrow cells is extremely important. However, typical classification machine learning systems only produce classification answers, and will not refuse to generate predictions when the prediction reliability is low. It will pose a big problem in some high-risk systems such as bone marrow cell recognition. This paper proposes a bone marrow cell classification method with rejected option (CMWRO) to classify 11 bone marrow cells. CMWRO is based on convolutional neural networks, ICP and SoftMax (CNN-ICP-SoftMax), containing a classifier with rejected option. When the rejected rate (RR) of tested samples is 0.3143, it can ensure that the precision, sensitivity, accuracy of the accepted samples reach 0.9921, 0.9917 and 0.9944 respectively. And the rejected samples will be handled by other ways, such as identified by doctors. Besides, the method has a good filtering effect on cell types that the classifier is not trained, such as abnormal cells and cells with less sample distribution. It can reach more than 82% in filtering efficiency. CMWRO improves the doctors’ trust in the results of accepted samples to a certain extent. They only need to carefully identify the samples that CMWRO refuses to recognize, and finally combines the two results. It can greatly improve the efficiency and accuracy of bone marrow cell recognition.